Author:
Ramzan Mohhammad,Hussain Afzal,Khan Tasneem,Siddique Mohd Usman Mohd,Warsi Musarrat Husain
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive Bladder Syndrome: Evaluation and Management. Curr Urol. 2018;11(3):117–25.
2. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4–20.
3. Sun F, Sui C, Zhou Y, Liu X, Shi Y, Wu Y, Li Y. Preparation, Characterization and Pharmacological Evaluation of Tolterodine Hydrogels for the Treatment of Overactive Bladder. Int J Pharm. 2013;454:532–8.
4. Chung DE, Te AE. Tolterodine extended-release for overactive bladder. Expert Opin Pharmacother. 2009;10(13):2181–94.
5. Rajabalaya R, Mun CY, Chellian J, Chakravarthi S, David SR. Transdermal Delivery of Tolterodine Tartrate for Overactive Bladder Treatment. In Vitro and in Vivo Evaluation Acta Pharm. 2017;67(3):325–39.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献